The GlaxoSmithKline PLC (GSK) Stake Maintained by Baker Ellis Asset Management LLC

The GlaxoSmithKline PLC (GSK) Stake Maintained by Baker Ellis Asset Management LLC

Baker Ellis Asset Management LLC held its position in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,000 shares of the pharmaceutical company’s stock at the end of the second quarter. Baker Ellis Asset Management LLC’s holdings in GlaxoSmithKline PLC were worth $130,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of GSK. Quadrant Capital Group LLC boosted its position in GlaxoSmithKline PLC by 6.4% in the second quarter. Quadrant Capital Group LLC now owns 2,725 shares of the pharmaceutical company’s stock worth $111,000 after buying an additional 163 shares during the last quarter. SignalPoint Asset Management LLC boosted its position in GlaxoSmithKline PLC by 18.5% in the second quarter. SignalPoint Asset Management LLC now owns 6,578 shares of the pharmaceutical company’s stock worth $285,000 after buying an additional 1,025 shares during the last quarter. Hamlin Capital Management LLC boosted its position in GlaxoSmithKline PLC by 0.6% in the second quarter. Hamlin Capital Management LLC now owns 1,463,148 shares of the pharmaceutical company’s stock worth $63,413,000 after buying an additional 9,117 shares during the last quarter. GW&K Investment Management LLC boosted its position in GlaxoSmithKline PLC by 7.1% in the second quarter. GW&K Investment Management LLC now owns 745,241 shares of the pharmaceutical company’s stock worth $32,299,000 after buying an additional 49,267 shares during the last quarter. Finally, Aviance Capital Management LLC boosted its position in GlaxoSmithKline PLC by 67.3% in the second quarter. Aviance Capital Management LLC now owns 877,233 shares of the pharmaceutical company’s stock worth $38,019,000 after buying an additional 352,748 shares during the last quarter. 8.79% of the stock is owned by hedge funds and other institutional investors.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded up 0.14% on Friday, reaching $42.96. 2,177,718 shares of the company’s stock traded hands. GlaxoSmithKline PLC has a 52 week low of $37.82 and a 52 week high of $45.58. The stock has a market capitalization of $104.41 billion, a PE ratio of 2685.00 and a beta of 0.89. The company has a 50 day moving average of $43.41 and a 200-day moving average of $42.86.

The firm also recently disclosed a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Friday, August 12th will be paid a dividend of $0.494 per share. The ex-dividend date of this dividend is Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio is currently 6,600.00%.

A number of research firms recently weighed in on GSK. Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Wednesday. Citigroup Inc. reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Friday, September 23rd. Piper Jaffray Cos. began coverage on shares of GlaxoSmithKline PLC in a research report on Friday, September 23rd. They set an “overweight” rating for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, September 22nd. Finally, Bank of America Corp. reaffirmed a “buy” rating and set a $50.00 price objective on shares of GlaxoSmithKline PLC in a research report on Tuesday, September 20th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. GlaxoSmithKline PLC has an average rating of “Hold” and a consensus target price of $47.86.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Related posts

Leave a Comment